Skip to content
Screener

ImmunityBio, Inc. IBRX Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

Merck & Co. logo
Merck & Co.MRK
$28.73B+11.4%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$8.1B+247%
Enterprise value$8.34B+233%
P/S57.4×+16.2×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 7:37 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001326110-26-000059
Line itemMarch 31, 2026 / Weighted- Average Life Remaining(in years)March 31, 2026 / Gross Carrying AmountMarch 31, 2026 / Accumulated AmortizationNet Carrying Amount
Definite-lived:
Favorable leasehold rights2.8$20,398$(8,946)$11,452
Developed technology4.3542(81)461
Total definite-lived assets20,940(9,027)11,913
Indefinite-lived:
Goodwill910910
In-process software development6262
Total indefinite-lived assets972972

ITEM 1. FINANCIAL STATEMENTS.

FAQ

What is ImmunityBio, Inc.'s finite-lived intangible assets, accumulated amortization?
ImmunityBio, Inc. (IBRX) reported finite-lived intangible assets, accumulated amortization of $9.03M in Q1 2026.
How has ImmunityBio, Inc.'s finite-lived intangible assets, accumulated amortization changed year-over-year?
ImmunityBio, Inc.'s finite-lived intangible assets, accumulated amortization increased by 41.6% year-over-year, from $6.38M to $9.03M.
What is the long-term trend for ImmunityBio, Inc.'s finite-lived intangible assets, accumulated amortization?
Over 3 years (2022 to 2025), ImmunityBio, Inc.'s finite-lived intangible assets, accumulated amortization has grown at a 60.2% compound annual growth rate (CAGR), from $1.94M to $7.96M.

Ask your AI about ImmunityBio, Inc.'s finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude